Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension

Código QR

Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension

Ines Lanzl,1 Thomas Hamacher,2 Klaus Rosbach,3 Mohammed Osman Ramez,4 Robert Rothe,5 Eva Ružicková,6 Marta Karhanová,7 Friedemann Kimmich81Private practice, Prien, Germany; 2Private practice, Starnberg, Germany; 3Private practice, Mainz, Germany; 4Private practice, Buxtehude, G...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lanzl I, Hamacher T, Rosbach K, Ramez MO, Rothe R, Růžičkov&aacute; E, Karhanov&aacute; M, Kimmich F
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/d3e0e4f3b3424315a02f16b0cdd73a45
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
por: Ermiş&nbsp;SS
Publicado: (2012)

Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
por: Ruangvaravate N, et al.
Publicado: (2020)

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study
por: Pillunat LE, et al.
Publicado: (2017)

Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost
por: Hommer A, et al.
Publicado: (2011)

Efficacy and tolerability of preservative-free tafluprost 0.0015% in Korean patients with glaucoma
por: Hwang YH
Publicado: (2013)

Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension
por: Dorota Pozarowska
Publicado: (2010)

Efficacy of preservative-free tafluprost in patients with normal-tension glaucoma previously treated with latanoprost
por: Sacchi M, et al.
Publicado: (2014)

Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension
por: Makoto Aihara
Publicado: (2010)

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
por: Gregory Katz, et al.
Publicado: (2010)

Tolerability and effectiveness of preservative-free dorzolamide&ndash;timolol (preservative-free Cosopt&reg;) in patients with open-angle glaucoma or ocular hypertension
por: Cindy Hutnik, et al.
Publicado: (2010)

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
por: Pillunat LE, et al.
Publicado: (2016)

Idiopathic intracranial hypertension in pediatric patients
por: Nada Jir&aacute;skov&aacute;, et al.
Publicado: (2008)

Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma
por: Janulevičienė I, et al.
Publicado: (2012)

Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
por: Baiza-Dur&aacute;n LM, et al.
Publicado: (2012)

Addition of a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension
por: Lorenz K, et al.
Publicado: (2011)

Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
por: Laube T, et al.
Publicado: (2012)

Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension
por: Pacella F, et al.
Publicado: (2012)

Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial
por: Dai Woo Kim, et al.
Publicado: (2021)

Topical Medication Therapy for Glaucoma and Ocular Hypertension
por: Tao Wang, et al.
Publicado: (2021)

The clinical effectiveness of tafluprost on Japanese normal-tension glaucoma patients
por: Nomura A, et al.
Publicado: (2018)

Glaucoma therapy: preservative-free for all?
por: Thygesen J
Publicado: (2018)

Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension
por: Sophia K Mirza, et al.
Publicado: (2010)

Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma
por: Inoue K, et al.
Publicado: (2013)

Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
por: Nicholas P Bell, et al.
Publicado: (2010)

Correlation between ocular perfusion pressure and ocular pulse amplitude in glaucoma, ocular hypertension, and normal eyes
por: Figueiredo BP, et al.
Publicado: (2013)

Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/ timolol among patients with open-angle glaucoma or ocular hypertension
por: Sanseau A, et al.
Publicado: (2013)

Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials
por: Uusitalo H, et al.
Publicado: (2016)

Development of ocular hypertension and persistent glaucoma after intravitreal injection of triamcinolone
por: M Selim Kocabora, et al.
Publicado: (2008)

Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension
por: Anna Galanopoulos, et al.
Publicado: (2008)

Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma
por: Liu Y, et al.
Publicado: (2012)

A biodegradable polymeric system for peptide–protein delivery assembled with porous microspheres and nanoparticles, using an adsorption/infiltration process
por: Alcal&aacute;-Alcal&aacute; S, et al.
Publicado: (2013)

Efficacy and safety of benzalkonium chloride-free fixed-dose combination of latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension
por: Bhagat P, et al.
Publicado: (2014)

Can macular translocation be a satisfactory management of subfoveal choroidal neovascular membrane?
por: &Aacute;rp&aacute;d Bereczki, et al.
Publicado: (2008)

Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension
por: Inoue K, et al.
Publicado: (2012)

Relationships between central corneal thickness and optic disc topography in eyes with glaucoma, suspicion of glaucoma, or ocular hypertension
por: Pinakin Gunvant, et al.
Publicado: (2008)

Central corneal thickness in black Cameroonian ocular hypertensive and glaucomatous subjects
por: Christelle Domngang Noche, et al.
Publicado: (2010)

Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study
por: Economou MA, et al.
Publicado: (2018)

Combination therapy or monotherapy for the depressed type of schizoaffective disorder
por: Lubomira Iz&aacute;kov&aacute;, et al.
Publicado: (2009)

Blood pressure, ocular perfusion pressure and open-angle glaucoma in patients with systemic hypertension
por: Cantor E, et al.
Publicado: (2018)

Acquired color vision and visual field defects in patients with ocular hypertension and early glaucoma
por: Dimitris Papaconstantinou, et al.
Publicado: (2009)